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Central giant cell lesion (CGCL) and peripheral giant cell lesion (PGCL) are non-neoplastic proliferative processes of the jaws. PGCL is a reactive process induced by irritant local 
factors and CGCL is an intra-osseous lesion of unknown etiology. Both lesions exhibit 
similar histologic features showing abundant mononuclear cells, admixed with a large 
number of multinucleated giant cells and a rich vascularized stroma with extravasated 
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fatty acid synthase (FASN) with angiogenesis. Objective: To evaluate angiogenesis and 
lymphangiogenesis and their relationship with FASN expression in CGCL and PGCL. Material 
and Methods: Thirteen CGCL and 14 PGCL of the jaws were selected for immunoexpression 
of FASN; CD34 and CD105 (to assess blood microvessel density [MVD] and microvessel 
area [MVA]); and D2-40 (to assess lymphatic MVD and MVA). Results: Within PGCL and 
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mononuclear cells were observed. Between PGCL and CGCL, only MVD-CD34 and all MVA 
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positive mononuclear cells in both lesions was observed. Conclusions: Our results show 
both lesions exhibiting similar levels of FASN expression and neoangiogenesis, suggesting 
constitutive processes that regulate tissue maintenance.
Keywords: Giant cell lesion. Immunohistochemistry. Angiogenesis. Lymphangiogenesis. 
Fatty acid synthase.
INTRODUCTION
Giant cell lesion (GCL) of the jaws is a non-
neoplastic proliferative process, divided into 
central giant cell lesion (CGCL) and peripheral 
giant cell lesion (PGCL). PGCL is considered a 
reactive process induced by local irritants on 
the gingiva or alveolar mucosa. CGCL is an 
intra-osseous lesion of unknown etiology11. Both 
CGCL and PGCL exhibit similar histopathological 
features, and are characterized by the presence 
of abundant mononuclear stromal cells, admixed 
with a large number of multinucleated giant cells 
and a rich vascularized stroma with extravasated 
erythrocytes, hemosiderin deposition, and blood-
	 In spite of this, these lesions may have 
different clinical behaviors11,13,23.
Fatty acid synthase (FASN) is the metabolic 
enzyme responsible for endogenous synthesis 
of saturated long-chain fatty acid, specifically 
palmitate, from the precursors acetyl-CoA and 
malonyl-CoA7. FASN is overexpressed in a variety 
of human cancers affecting breast19, ovaries2, 
prostate20, and oral cavity22, whereas FASN is 
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downregulated in most normal human tissues 
(except in the liver, lactating breast, fetal lung, 
and adipose tissue) because cells preferentially 
use circulating dietary fatty acids for the synthesis 
of new structural lipids29. In the oral cavity, 
FASN expression has been shown in squamous 
cell carcinoma and melanoma3,22; however, 
its expression in benign neoplasms3 and/or 
reactive conditions is little known. Interestingly, 
some studies have linked FASN expression with 
endothelial cell proliferation4,21. Accordingly, the 
role of FASN expression in angiogenesis must be 
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in GCL of the jaws is unknown.
CD34 is a cell surface glycoprotein consistently 
expressed in the vascular endothelium. Some studies 
have previously assessed CD34 expression in CGCL 
in order to compare aggressive and non-aggressive 
subtypes. They showed increased microvessel 
density (MVD)-CD34 in aggressive CGCL10,18,25. 
Although CD34 is unable to distinguish between 
pre-existing vessels and neoformed vessels, 
interestingly, it has been shown that distinguishing 
neoformed vessels in proliferative tissues is relevant 
and may have prognostic implications, identifying 
possible targets for developing anti-angiogenic 
therapeutic strategies5,18. CD105 (endoglin) is 
an angiogenic membrane protein that is highly 
expressed in neoformed vessels6. Although CD105 
has been assessed in oral vascular malformations 
and pyogenic granulomas26, to our knowledge, CD105 
expression in GCL of the jaws is unknown. Another 
unclear and relevant point is the characterization of 
the lymphatic MVD (LMVD) in GCL, which may be 
immunohistochemically evaluated through the D2-
40 marker13. Nevertheless, as in the case of CD105, 
the lymphatic vascular stroma characterization in 
GCL of the jaws has not been evaluated.
As previously mentioned, increased FASN 
expression in oral malignant tumors has been 
reported3,22, and some studies have linked FASN 
expression with endothelial cell proliferation4,21. 
It remains to be determined what happens with 
such events in oral benign and/or reactive lesions. 
Thus, the aim of the current study was to assess 
angiogenesis and lymphangiogenesis, as well as 
establishing their relationship with FASN expression 
in CGCL and PGCL of the jaws.
MATERIAL AND METHODS
This retrospective study examined the records 
and tissues of patients diagnosed and treated for 
GCL of the jaws. None of the patients had received 
any treatment with a therapeutic agent prior to 
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paraffin-embedded tissue blocks of 13 CGCL 
(8 males, 5 females; mean age 18.5 years; 8 
mandible, 5 maxilla) and 14 PGCL (9 males, 5 
females; mean age 38.9 years; 11 mandibular 
gingiva, 3 maxillary gingiva) were selected 
from our laboratory archives. According to their 
clinical characteristics, such as painful symptoms, 
growth pattern rate, root resorption, cortical bone 
perforation and recurrence, the CGCL cases of the 
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8. 
All lesions were reviewed through hematoxylin-
eosin stained slides and the diagnosis was 
$	KJ
from the study were GCL cases which presented 
inadequate clinical description, cases diagnosed 
as aneurysmal bone cyst, cherubism and brown 
tumor of hyperparathyroidism (confirmed by 
establishing elevated serum parathyroid hormone 
	Q
	$		$	+
for histological analysis. This study was approved by 
the Research Ethics Committee (Process 042/2011).
Immunohistochemical methods
For each antibody (FASN, CD34, CD105 and D2-
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glass slides were used. All tissue specimens were 
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and cut into parallel consecutive sections. For the 
immunohistochemical (IHC) reactions, the slides 
were hydrated and treated with hydrogen peroxide 
(3%). Primary antibodies, dilutions and antigen 
retrieval are shown in Table 1. The tissue sections 
were then washed three times in phosphate buffered 
saline (PBS) solution and exposed to secondary 
antibody using the LSAB+Kit (Dako, Carpinteria, 
CA, USA). Peroxidase activity was visualized by 
using the chromogen diaminobenzidine (DAB) 
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Table 1- Antibodies used for immunohistochemical analysis of central and peripheral giant cell lesions
?	E Clone Manufacturer Dilution +:
FASN 23/610962 Becton Dickinson Transduction 
Laboratories1
1:200 TRIS/EDTA (pH 9.0)
CD34 QBEnd10 Dako# jan/ 1:50 Citric acid (pH 6.0)
CD105 SN6h Dako jan/ 1:30 Proteinase K
D2-40 D2-40 Dako 1:100 Citric acid (pH 6.0)
1Lexington, KY, USA. # Carpinteria, CA, USA
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(Sigma Chemical Co., St. Louis, USA). Finally, the 
tissue sections were counterstained with Carrazi´s 
hematoxylin for 5 minutes. Thereafter, the sections 
were dehydrated in a series of graded ethanol 
solutions, diaphanized and mounted in Canada 
balsam under cover glasses. Sections of oral 
Kaposi’s sarcomas were included in all reactions as 
positive control for CD34, CD105 and D2-40, while 
prostate carcinomas were used for FASN. Negative 
controls of reactions were performed by omitting 
the primary antibody. The slides were scanned and 
photographed using the Aperio Scanscope CS Slide 
Scanner (Aperio Technologies®, Vista, CA, USA).
Immunostaining assessment and 
statistical analysis
MVD and microvessel area (MVA), assessed 
through CD34 and CD105 expression, as well as 
lymphatic MVD (LMVD) and MVA (LMVA), assessed 
through D2-40 expression, were established 
identifying the most vascularized areas within 
the lesions (“hot spots”), which were chosen 
at low magnification (100x) and subsequently 
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the Aperio Scan Scope® software, which depicted 
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area, respectively, of positive microvessels stained 
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MVD and MVA. The MVA measurement was done 
by means of vascular contour tracing using the 
Image J® software, which automatically measured 
}|2). Single endothelial cells 
or clusters of endothelial cells, with or without a 
lumen, were considered to be individual vessels.
To assess FASN expression, similar to angiogenic 
markers, the area containing a high number of 
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positive mononuclear cells and multinucleated 
giant cells in both lesions were counted in each 
high-power field using the software Image J® 
(Scion Corporation, USA), and then the average 
percentages of the immunostained cells were 
calculated in each case.
The data collected were recorded and organized 
in a database using Statistical Package for Social 
Science (version 17.0; SPSS Inc., Chicago, IL, USA). 
Normal distribution was tested using the Shapiro–
Wilk test. In samples with a normal distribution, the 
Student t-test and Pearson correlation were applied. 
In samples that presented non-normal distributions, 
the Mann–Whitney U test and Spearman correlation 
were applied. A P<0.05 probability value was 
				%
RESULTS
All vascular structures in all cases were 
highlighted by CD34. By comparing the MVD within 
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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CD105-positive vessels than CD34-positive vessels 
(P<0.001) was observed (Table 2). In addition, a 
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Table 2- Comparison between PGCL and CGCL in relation to (L)MVD, (L)MVA, and percentage of FASN-positive 
multinucleated giant cells and mononuclear cells
V?: n p V?: n p
PGCL CGCL
MVD-CD34 14  MVD-CD34 13 
MVD-CD105 14 MVD-CD105 13
MVD-CD34 14  MVD-CD34 13 .001
LMVD-D2-40 14 LMVD-D2-40 13
MVD-CD105 14 .015 MVD-CD105 13 .008
LMVD-D2-40 14 LMVD-D2-40 13
FASN+ MGC 14 .002 FASN+ MGC 13 .004
FASN+ MC 14 FASN+ MC 13
MVA-CD34 14  MVA-CD34 13 
MVA-CD105 14 MVA-CD105 13
MVA-CD34 14  MVA-CD34 13 
LMVA-D2-40 14 LMVA-D2-40 13
MVA-CD105 14  MVA-CD105 13 
LMVA-D2-40 14 LMVA-D2-40 13
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than CD105-positive vessels in PGCL (P''&*Q
and CGCL (P'''Q$	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
percentage indicates that 31% and 13% of the 
vessels in PGCLs, and 33% and 8% of the vessels 
in CGCLs were positive for CD105 and D2-40, 
respectively. 
The number of CD34-positive vessels was 
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(Figures 1a, 1b; Figure 2a). However, no statistical 
difference regarding the number of CD105- and D2-
40-positive vessels was found when comparing both 
lesions (Figures 1c, 1d; Figure 2a; Figures 3a, 3b). 
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greater MVA for all vascular markers used in 
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2b). Moreover, when comparing the MVA within 
<
	%		
of CD105-positive vessels than CD34-positive 
vessels (P<0.001) was observed. In addition, it 
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D2-40-positive vessels than CD105-positive vessels 
in both lesions (P<0.001) (Table 2). 
Moreover, through consecutive section analysis, 
we found focal areas showing vessels stained with 
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# Comparison between PGCL and CGCL in relation to MVD and LMVD (a), MVA and LMVA (b) and percentage of 
FASN-positive MGC and MC (c)
P# Immunoexpression of CD34 in CGCL (a, 400x) and PGCL (b, 400x), almost all vessels were CD34-positive in 
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lesser number of CD105-positive vessels was observed in CGCL than in PGCL
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CD105 and D2-40 in both lesions (Figures 3c, 3d), 
supporting the idea that some CD105-stained 
vessels represent newly formed lymphatic vessels. 
All cases present FASN-positive multinucleated 
giant cells (PGCL, mean 39%; CGCL, mean 36%) 
and mononuclear cells (PGCL, mean 7%; CGCL, 
mean 10%) (Figure 2c; Figures 4a, 4b), without 
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We also observed focal areas showing weak FASN 
immunoexpression on endothelial cells in 46% and 
21% of the CGCL and PGCL cases, respectively. 
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found between MVA-CD105 with FASN-positive 
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DISCUSSION
Both CGCL and PGCL of the jaws exhibit similar 
histopathological features, being characterized by 
numerous ovoid and spindle-shaped mononuclear 
cells, admixed with multinucleated giant cell, within 
a rich vascularized stroma11,16. Despite this, it is 
well known that these lesions may have different 
clinical behaviors23. In the current study, without 
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all cases presented FASN-positive multinucleated 
giant cells and mononuclear cells. Nevertheless, we 
observed a higher number of multinucleated giant 
cells than mononuclear cells (ratio 4:1) presenting 
FASN immunoreactivity. It is probable that cell 
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may help to explain our results. Moreover, as a 
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multinucleated giant cells and mononuclear cells16 
is most probably associated with angiogenesis 
in GCL, on the other hand the lack of correlation 
between FASN-positive multinucleated giant cells 
with vascular markers observed in the current study 
can suggest maintenance and/or remodeling role 
for FASN expression in multinucleated giant cells. 
Angiogenesis, which is the formation of new 
vessels from pre-existing vessels, is thought to be of 
crucial importance to the growth and maintenance 
of proliferative tissues24. In the oral cavity, it has 
been shown that the number and size of blood 
vessels increase from normal oral epithelium 
through dysplastic epithelium to reach a maximum 
in invasive carcinoma1, while no significant 
difference seems to occur between normal mucosa, 
hyperplasia, and dysplasia for LMVD. Conversely, 
invasive carcinomas presented higher LMVD 
P# Immunoexpression of D2-40 in CGCL (a, 400x) and PGCL (b, 400x), notice that the lymphatic vessels are of 
larger diameter in PGCL than in CGCL. This case of CGCL on parallel consecutive sections presented vessels positive for 
both CD105 (c, 400x) and D2-40 (d, 400x), suggesting neolymphangiogenesis
P#D Immunoexpression of FASN in CGCL (a, 400x) and PGCL (b, 400x), note immunopositivity for FASN in the 
multinucleated giant cells and mononuclear cells in both lesions
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than normal mucosa and precancerous lesions17. 
Regarding benign and reactive oral lesions, several 
studies have been performed to quantify MVD by 
using CD34 and CD1059,10,12,18,25-27, but none of 
them have assessed GCL considering both markers. 
In addition, although D2-40 expression has been 
demonstrated in normal odontogenic tissues as 
well as in cystic and tumor odontogenic lesions30, 
it is noteworthy that in GCL a stromal lymphatic 
vessel characterization has not been performed. 
Like CD105, D2-40 expression in GCL is unknown.
In the current study, we have observed uniform 
positivity for CD34 in all vascular structures in 
both lesions. Almost all our cases (93% and 92% 
of the PGCL and CGCL, respectively) exhibited 
CD105-positive vessels (about 32%, in relation 
to CD34-positive vessels), while only 78% and 
69% of the PGCL and CGCL, respectively, showed 
D2-40-positive vessels (about 10%, in relation 
to CD34-positive vessels). Thus, the constitutive 
expression of CD105 in GCL supports angiogenic 
activity and tissue remodeling. This is further 
supported by FASN expression in endothelial cells, 
detected focally in about 46% and 21% of CGCL and 
PGCL cases, respectively. Moreover, the expression 
of endothelial markers in GCL is consistent with 
the presence of various angiogenic factors and 
matrix metalloproteinases (MMPs), such as tumor 
necrosis factor-alpha (TNF-α), transforming growth 
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(b-FGF), vascular endothelial growth factor (VEGF), 
and MMP-915,16,28. Since it has been shown that 
aggressive rather than nonaggressive subtypes 
of CGCL present higher MVD-CD3410,18,25, further 
studies are needed in order to compare whether 
there are CD105 expression differences between 
aggressive and nonaggressive subtypes of CGCL. In 
relation to stromal lymphatic vessel characterization, 
it is interesting that lymphangiogenesis in reactive 
or benign oral lesions have been little studied. 
In the current study, we have shown that about 
8% and 13% of the vessels in CGCL and PGCL 
group, respectively, were immunoreactive for 
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is suggested that the higher number of lymphatic 
vessels detected in PGCL (Figure 2) seems to 
be influenced by anatomical location, since a 
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be observed at the periphery of the lesions in close 
association with the lamina propria. Furthermore, 
through consecutive section analysis, we found 
focal areas showing vessels stained with CD105 
and D2-40, in both lesions. In order to validate 
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CD105 and D2-40 in oral GCL should be compared 
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neolymphangiogenesis in these lesions.
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greater MVA than CGCL for all vascular markers 
used. Similar results were shown27, which favored 
a reactive nature for PGCL. It is likely that, in 
addition to the anatomical location of these 
lesions, differences in the expression pattern of 
angiogenic growth factors1,16 may help to explain 
the differences found in our study. It has been 
shown that FASN inhibition by orlistat may reduce 
endothelial cell proliferation and angiogenesis4. 
As previously commented, to our knowledge, the 
FASN immunoexpression in giant cell lesions is 
unknown. However, in our study, different from 
FASN-positive multinucleated giant cells, it is 
	%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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+
between FASN-positive mononuclear cells and MVA-
!&'*			+	%	

is suggested that FASN-positive mononuclear cells 
may contribute with new vessel formation. Future 
				%	
determinate possible interactions between FASN 
expression and angiogenic proteins in GCL.
CONCLUSION
In summary, our results suggest that greater 
MVD-CD34, and greater MVA-CD34, CD105 
and D2-40, in PGCL rather than in CGCL, might 
be associated with a reactive inflammatory 
process. Moreover, similar levels of FASN 
expression, neoangiogenesis (MVD-CD105), and 
lymphangiogenesis (LMVD-D2-40) between PGCL 
and CGCL indicate constitutive processes to regulate 
tissue maintenance and remodeling in both lesions. 
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